This can indicate, as observed in the increased cell viability to abiraterone upon miR-182-5p inhibition, a distinct mode of action (tumor suppressor-like) of miR-182-5p in regulating E-Cadherin or an indirect mechanism through the regulation of other EMT downstream targets. The gene discussed is CDH1; the disease is neoplasm.